Trial · NCT06394570
Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer
NCT06394570, Phase 1, Phase 2, Recruiting, University of Texas Southwestern Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer. Trials, record NCT06394570. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06394570
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer
- NCT number
- NCT06394570
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 19 participants, estimated
- Lead sponsor
- University of Texas Southwestern Medical Center
- Conditions
- Bladder Cancer
- Interventions
- Enfortumab vedotin
- First posted
- 2024-05-01
- Last updated
- 2026-09-30
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Tolerated Dose (MTD) Regimen | From initiation of Enfortuman Vedotin treatment until post neoadjuvant therapy visit (approximately 120 days) | A standard 3 + 3 dose escalation schedule will be used for all escalations. Enfortumab Vedotin will be given for three 21 day cycles. Radiation therapy will be administered at dose level 0, level 1 or level 2. |
| Primary | Pathologic Complete response rate at radical cystectomy | At radical cystectomy following completion of neoadjuvant therapy (approximately 6 weeks after completion of EV treatment) | Rate of complete pathologic response in bladder tumor biopsy at cystectomy according to postsurgical staging. |
| Secondary | Adverse Events | From initiation of neoadjuvant therapy to completion of final post treatment study visit (approximately 4 months) | Adverse events reported and observed according to CTCAE v5.0 |
| Secondary | Rate of pathologic downstaging in the bladder | At radical cystectomy following completion of neoadjuvant therapy (approximately 6 weeks after completion of EV treatment) | Rate of post surgical pathologic staging being less than clinical staging. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06394570
GET https://conductscience.org/api/trials/v1/NCT06394570/registered